NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

There are other types of IP including biologic exclusivity which protects a biologic from biosimilars for ten years from the date it is approved. If you think that’s not enough, there is data exclusivity, which prevents other companies from using DCVax trial data to prove safety and efficacy. On top of that, DCVax-Direct has patents on method B+ out to 2036. Additionally, DCVax-l + checkpoint inhibitor is patented in several places, including Europe out to 2036.